-
表皮生长因子受体(epidermal growth factor receptor, EGFR)是ErbB(一种酪氨酸激酶受体)家族的一员, 即ErbB1。由于它在多种肿瘤中过表达和(或)异常表达, 与肿瘤的发生、发展关系密切, 故其研究进展倍受关注[1]。
目前的广泛研究证实, EGFR在头颈部鳞状细胞癌中的表达量达90%~100%、肾癌达50%~90%、肺癌达40%~80%、乳腺癌达14%~90%、结直肠癌达25%~77%、卵巢癌达25%~70%、前列腺癌达39%~47%, 此外, 其过度表达在神经系统肿瘤、胃癌、胸腺肿瘤等中也均有报道。EGFR的过度表达常预示肿瘤患者预后差, 肿瘤转移快, 对放化疗抗拒, 激素耐药及生存期较短等[2-5]。
靶向治疗具有高效、低不良反应的特点, 已成为肿瘤治疗的研究热点。靶向治疗的出现, 不但为肿瘤患者带来新的希望, 而且为其治疗提供了一种全新的思路。虽然很多靶向治疗药物已进入临床应用, 但是如何通过检测某些特异性指标以评估其疗效, 仍需进一步研究。PET-CTEGFR显像可以反映EGFR的活性, 可能成为检测EGFR更可靠的指标。本文主要对肿瘤分子靶向治疗中PET-CTEGFR显像剂的研究进展进行综述。
PET-CT表皮生长因子受体显像的研究进展
Study progress of PET-CT epidermal growth factor receptor imaging
-
摘要: 对肿瘤患者来说表皮生长因子受体(EGFR)是一个很有吸引力的的治疗靶点,PET-CT EGFR显像可以反映EGFR的活性,可能成为检测EGFR更可靠的指标。近年来,用PET-CTEGFR显像筛选肿瘤靶向治疗药物已经成为PET-CT临床应用研究的热点和重点。
-
关键词:
- 受体, 表皮生长因子 /
- 正电子发射断层显像术 /
- 体层摄影术, X线计算机
Abstract: Epidermal growth factor receptor (EGFR) is a promising therapeutic target for cancer patients.Its activity can be reflected by PET-CTEGFR imaging which became a more reliable indicator to measure EGFR.In recent years, PET-CTEGFR imaging was adopted to screen targeted drugs, which became a hot topic in the clinical application of PET-CT. -
[1] Moghal N, Sternberg PW. Multiple positive and negative regulators of signaling by the EGR-receptor. Curr Opin Cell Biol, 1999, 11(2): 190-196. doi: 10.1016/S0955-0674(99)80025-8 [2] Capdevila J, Elez E, Maearulla T, et al. Anti-epidermalgrowth factor receptor monoclonal antibodies in cancer treatment. Cancer Treat Rev, 2009, 35(4): 354-363. doi: 10.1016/j.ctrv.2009.02.001 [3] Casanova ML, Larcher F, Casanova B, et al. A critical role for rasmediated, epidermal growth factor receptor-dependent angiogenesis in mouse skin carcinogenesis. Cancer Res, 2002, 62(12): 3402-3407. [4] Sasaki T, Kitadai Y, Nakamura T, et al. Inhibition of epidermal growth factor receptor and vascular endothelial growth factor receptor phosphorylation on tumor-associated endothelial cells leads to treatment of orthotopic human colon cancer in nude mice. Neopla-sia, 2007, 9(12): 1066-1077. doi: 10.1593/neo.07667 [5] Galizia G, Lieto E, Ferraraccio F, et al. Prognostic significance of epidermal growth factor receptor expression in colon cancer patients undergoing curative surgery. Ann Surg Oncol, 2006, 13(6): 823-835. [6] Varella-Garcia M, Diebold J, Eberhard DA, et al. EGFR fluorescence in situ hybridisation assay: guidelines for application tononsmall-cell lung cancer. J Clin Pathol, 2009, 62(11): 970-977. doi: 10.1136/jcp.2009.066548 [7] Pirker R, Pereira JR, Szczesna A, et al. Cetuximab plus chemotherapy in patientswith advanced non-small-cell lung cancer(FLEX): an open-label randomised phase Ⅲ trial. Lancet, 2009, 373(9674): 1525-1531. doi: 10.1016/S0140-6736(09)60569-9 [8] Yarden Y, Sliwkowski MX. Untangling the Erb B signalling network, Nat Rev Mol Cell Biol, 2001, 2(2): 127-137. doi: 10.1038/35052073 [9] Linardou H, Dahabreh IJ, Bafaloukos D, et al. Somatic EGFR muta-tions and efficacy of tyrosine kinase inhibitors in NSCLC. Nat Rev Clin Oncol, 2009, 6(6): 352-366. [10] Giaccone G, Johnson D, Scagliotti GV, et al. Results of amultivariate analysis of prognostic factors of overall survival of patients with advanced non-small-cell lung cancer (NSCLC) treated with gefitinib (ZD1839) in combination with platinum-based chemotherapy (CT) in two large Phase Ⅲ trials (INTACT 1 and 2). Proc Am Soc Clin Oncol, 2003, 22: 627. [11] Kanteti R, Yala S, Ferguson MK, et al. MET, HGF, EGFR, and PXN gene copy number in lung cancer using DNA extracts from FFPE archival samples and prognostic significance. J Environ Pathol Toxicol Oncol. 2009, 28(2): 89-98. doi: 10.1615/JEnvironPatholToxicolOncol.v28.i2.10 [12] Fredriksson A, Johnström P, Thorell JO, et al. In vivo evaluation of the biodistribution of 11C-labeled PD153035 in rats without and with neuroblastoma implants. Life Sci, 1999, 65(2): 165-174. doi: 10.1016/S0024-3205(99)00233-7 [13] Rae JM, Lippman ME. Evaluation of novel epidermal growth factor receptor tyrosine kinase inhibitors. Breast Cancer Res Treat, 2004, 83(2): 99-107. doi: 10.1023/B:BREA.0000010702.10130.29 [14] Wang H, Yu JM, Yang GR, et al. Further characterization of the epidermal growth factor receptor ligand 11C-PD153035, Chin Med J (Eng1), 2007, 120(11): 960-964. doi: 10.1097/00029330-200706010-00004 [15] Cole GW Jr, Alleva AM, Reddy RM, et al. The selective epidermal growth factor receptor tyrosine kinase inhibitor PD153035 suppresses expression of prometastasis phenotypes in malignant pleural mesothelioma cells in vitro. J Thorac Cardiovasc Surg, 2005, 129(5): 1010-1017. [16] Pal A, Glekas A, Doubrovin M, et al. Molecular imaging of EGFR kinase activity in tumors with 124Ⅰ-labeled small molecular tracer and positron emission tomography. Mol Imaging Biol, 2006, 8(5): 262-277. doi: 10.1007/s11307-006-0049-0 [17] CaiW, Chen K, He L, et al. Quantitative PET of EGFR expression in xenograft-bearing mice using 64Cu-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody. Eur J Nucl Med Mol Imaging, 2007, 34(6): 850-858. doi: 10.1007/s00259-006-0361-6 [18] Abourbeh G, Dissoki S, Jacobson O, et al. Evaluation of radiolabeled ML04, a putative irreversible inhibitor of epidermal growth factor receptor, as a bioprobe for PET imaging of EGFR-overexpressing tumors. Nucl Med Biol, 2007, 34(1): 55-70. [19] Fredriksson A, Stone-Elander S. PET screening of anticancer drugs. A faster route to drug/target evaluations in vivo. Methods Mol Med, 2003, 85: 279-294.
计量
- 文章访问数: 1867
- HTML全文浏览量: 702
- PDF下载量: 3